Initial Treatment Approach for Granulomatosis with Polyangiitis (GPA) with c-ANCA

Disease Overview

• GPA is a systemic necrotizing vasculitis characterized by granulomatous inflammation affecting small to medium-sized vessels, and without treatment, it has a poor prognosis with a median survival of approximately 5 months 1

Initial Treatment Approach

• The American College of Rheumatology/Vasculitis Foundation 2021 guidelines conditionally recommend rituximab over cyclophosphamide for remission induction 1
• Rituximab has been shown to be at least as effective as cyclophosphamide for remission induction in severe GPA 2

Treatment Considerations

• A reduced-dose glucocorticoid regimen during the first 6 months of therapy is preferred to minimize toxicity 3, 4
• Disease severity should guide treatment decisions, with rituximab preferred for severe disease 1
• Pneumocystis jirovecii pneumonia prophylaxis is recommended for patients receiving rituximab 6
• For maintenance therapy after remission, rituximab is the preferred agent 2

Important Considerations to Avoid

• Delaying treatment initiation can significantly worsen outcomes due to the potentially rapid progression of the disease 1
• Inadequate glucocorticoid tapering can lead to unnecessary treatment-related complications 3
• Failing to provide prophylaxis against Pneumocystis jirovecii pneumonia increases risk of opportunistic infections 6